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Abstract
Background: The extracellular signal-regulated kinase-1 and 2 (ERK1/2) proteins play an important role in cancer
cell proliferation and survival. ERK1/2 proteins also are important for normal cell functions. Thus, anti-cancer
therapies that block all ERK1/2 signaling may result in undesirable toxicity to normal cells. As an alternative, we
have used computational and biological approaches to identify low-molecular weight compounds that have the
potential to interact with unique ERK1/2 docking sites and selectively inhibit interactions with substrates involved
in promoting cell proliferation.
Methods: Colony formation and water soluble tetrazolium salt (WST) assays were used to determine the effects of
test compounds on cell proliferation. Changes in phosphorylation and protein expression in response to test
compound treatment were examined by immunoblotting and in vitro kinase assays. Apoptosis was determined
with immunoblotting and caspase activity assays.
Results: In silico modeling was used to identify compounds that were structurally similar to a previously identified
parent compound, called 76. From this screen, several compounds, termed 76.2, 76.3, and 76.4 sharing a
common thiazolidinedione core with an aminoethyl side group, inhibited proliferation and induced apoptosis of
HeLa cells. However, the active compounds were less effective in inhibiting proliferation or inducing apoptosis in
non-transformed epithelial cells. Induction of HeLa cell apoptosis appeared to be through intrinsic mechanisms
involving caspase-9 activation and decreased phosphorylation of the pro-apoptotic Bad protein. Cell-based and in
vitro kinase assays indicated that compounds 76.3 and 76.4 directly inhibited ERK-mediated phosphorylation of
caspase-9 and the p90Rsk-1 kinase, which phosphorylates and inhibits Bad, more effectively than the parent
compound 76. Further examination of the test compound’s mechanism of action showed little effects on related
MAP kinases or other cell survival proteins.
Conclusion: These findings support the identification of a class of ERK-targeted molecules that can induce
apoptosis in transformed cells by inhibiting ERK-mediated phosphorylation and inactivation of pro-apoptotic
proteins.
Background
The extracellular signal-regulated kinases-1 and 2 (ERK1/
2) proteins are members of the mitogen activated protein
(MAP) kinase superfamily that regulate cell proliferation
and survival. ERK1/2-mediated cell survival occurs
through protection against apoptosis by inactivating pro-
apoptotic proteins. For example, ERK proteins promote
cell survival by inhibiting caspase-9 [1,2] or Bim (Bcl-2-
interacting mediator of cell death) through direct phos-
phorylation [3]. Indirect inhibition of apoptosis occurs
through ERK phosphorylation and activation of p90Rsk-1,
which phosphorylates the pro-apoptotic Bad (Bcl-xL/Bcl-2
associated death promoter) protein and causes 14-3-3-
mediated sequestering that prevents interactions with the
pro-survival protein Bcl-2 [4,5]. Thus, constitutive activa-
tion of the ERK1/2 pathway through mutations in
upstream receptors, Ras G-proteins, and kinases, such as
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advantage [6-8].
Significant effort has gone into developing molecules
that inhibit proteins in the ERK1/2 pathway [9,10].
These drug discovery efforts include monoclonal antibo-
dies and small molecules that inhibit receptor tyrosine
kinases, Ras G-proteins, Raf, or MEK proteins [9,11-13].
Although some of these therapies have shown promising
clinical results, toxicity to skin, cardiac, and gastrointest-
inal tissue has been reported [14,15]. The toxicity asso-
ciated with upstream inhibition of ERK1/2 signaling is
likely due to the effects on the ERK pathway in normal
tissue and the various ERK1/2 substrates that regulate
cellular functions [6,16]. Thus, inhibition of specific
ERK functions, such as regulation of pro-apoptotic pro-
teins, may be an alternative approach to alleviating toxic
side effects resulting from complete inhibition of ERK
signaling by compounds targeting upstream proteins. To
test this, we have identified molecules that act indepen-
dent of the ATP binding site and are predicted to be
selective for ERK1/2 substrate docking domains [17,18].
By developing compounds that are substrate selective,
our goal is to inhibit ERK functions that are associated
with cancer cell survival but preserve ERK functions in
normal non-cancerous cells.
ERK1/2 are proline-directed serine/threonine kinases
that phosphorylate substrate protein sequences contain-
ing, at minimum, a proline in the +1 position (S/TP
site). Proline in the -2 position (PXS/TP sequence) may
also determine phosphorylation specificity [19]. While
this consensus sequence is shared by the other MAP
kinases proteins, including p38 MAP kinases, c-Jun N-
terminal kinases (JNKs), and ERK5, each MAP kinase
retains substrate specificity suggesting that other deter-
minants of kinase-substrate interactions are involved.
Currently, two distinct docking domains on substrates
have been identified to mediate interactions between
protein substrates and MAP kinases [19-22]. The D-
domain or DEJL site (docking site for ERK or JNK,
LXL), consists of two or more basic residues, a short
peptide linker, and a cluster of hydrophobic residues.
ERK1/2 substrates containing D-domains include ELK-1,
p90Rsk-1, MKP-3, and caspase-9 [1,23,24]. D-domains
have been found on substrates for ERK, JNK, and p38
MAP kinases [25,26]. MAP kinase substrates may also
c o n t a i na nF - s i t eo rD E F( docking site for ERK, FXF)
motif, which contains the consensus FXFP motif. The
F-site is 6-20 amino acids C-terminal to the phosphory-
lation site [19] is also found on ELK-1 as well as sub-
strates like KSR and nucleoporins [27].
Specific residues on MAP kinases form docking
domains that determine binding specificity with sub-
strate proteins. ERK1/2 and other MAP kinases contain
a common docking (CD) domain, which includes
aspartate residues 316 and 319 (labeled for ERK2) that
are located on the side opposite of the TXY activation
loop [25] and mediates interactions with the substrate
D-domains [27,28]. While the CD domain shares com-
mon features among MAP kinases, differences in the
CD domains and adjacent residues of ERK1/2 and p38
MAP kinases may be responsible for determining the
specificity of substrate interactions [29]. The F-site con-
taining substrates are thought to form hydrophobic
interactions with ERK1/2 on a F-site recruitment site
(FRS), which consists of leucines 198, 232, 235 and tyro-
sines 231 and 261 residues (labeled for ERK2) located
near the TXY activation site [27].
We have previously utilized computer aided drug
design (CADD) to identify low-molecular weight
(LMW) compounds that are predicted to interact near
the ERK2 CD domain and selectively disrupt ERK2
interactions with substrate proteins [17,18]. These stu-
dies identified several compounds that inhibited ERK1/
2’s ability to phosphorylate selected substrate proteins
but not affect the overall activity of the ERK enzyme
supporting the goal of using small molecules to inhibit
productive protein-protein interactions. Moreover, some
of the compounds tested did not appear to affect the
ability for the related p38 MAP kinase to phosphorylate
substrate proteins [18]. In addition to inhibiting ERK
substrate phosphorylation, several compounds identified
inhibited cell proliferation. In the current studies, we
have identified a class of structurally similar compounds
that inhibit cell proliferation and cause rapid induction
of apoptosis in transformed cancer cell lines. Apoptosis
appeared to occur through an intrinsic mechanism
involving the prevention of ERK2-mediated inhibition of
caspase-9 and p90Rsk-1 phosphorylation of the pro-
apoptotic protein Bad. In addition, transformed cells
appeared more sensitive to the growth inhibitory effects
of the test compounds as compared to non-transformed
epithelial cells. These findings support the identification
of novel LMW compounds that target ERK1/2 proteins
and restore apoptosis responses in cancer cells by
preventing phosphorylation events that inactivate pro-
apoptotic proteins.
Methods
Cells and reagents
HeLa S3 (human cervical carcinoma) and retinal pig-
ment epithelial cells that stably express human telomer-
ase (hTERT-RPE) were purchased from American Type
Culture Collection (ATCC, Manassas, VA) and main-
tained in complete medium consisting of Dulbecco’s
modified Eagle medium (DMEM) plus 10% fetal bovine
serum (FBS, Atlanta Biologicals, Lawrenceville, GA) and
antibiotics (Penicillin, 100 U/ml; Streptomycin, 100 μg/
ml) (Invitrogen, Carlsbad, CA). Hygromycin B, 0.01 mg/
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tion for the hTERT-RPE cells. Epidermal growth factor
(EGF) and etoposide were purchased from Sigma (St.
Louis, MO) and used at final concentrations of 25 ng/ml
and 50 μM, respectively. The ERK (pT183/pY185) and a-
tubulin antibodies were purchased from Sigma. Antibodies
against phosphorylated Bad (pS112 or pS136), total Bad,
phosphorylated Rsk-1 (pT573), phosphorylated Akt sub-
strates (RXRXXpS/T), Mcl-1, phosphorylated caspase-9
(pT125), and total caspase-9 were purchased from Cell
Signaling (Beverly, MA). Antibodies against poly ADP-
ribose polymerase (PARP), total Rsk-1, and ERK5 were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). U0126, SB203580, and Akt Inhibitor I were pur-
chased from Calbiochem and used at final concentrations
of 10 μM, 20 μM, and 25 μM, respectively. LY294002 was
purchased from Cell Signaling and used at a final concen-
tration of 25 μM. Test compounds were purchased from
Chembridge (San Diego, CA) and stored as 25 mM stock
solutions in DMSO. The general caspase inhibitor,
Z-VAD-FMK, was purchased from BD Biosciences (San
Jose, CA) and used at a final concentration of 20 μM.
Protein expression
Plasmids for mammalian and bacterial expression of cas-
pase-9 (catalytically inactive C287A mutant) were pur-
chased from Addgene (catalog #11819 and 11830). The
His6-tagged caspase-9 (C287A) was purified from BL21
(DE3) cells as described [30]. Briefly, BL21(DE3) cells
were induced with 0.2 mM isopropyl b-D-1-thiogalacto-
pyranoside for 4 hours and harvested with BugBuster
protein extraction reagent (EMD Biosciences, San Diego,
CA). Lysates were loaded onto a Talon Co
2+-I M A C
affinity resin column (BD Biosciences, San Jose, CA)
and eluted with imidazole. GST-p90Rsk-1 was expressed
and purified as previously described [31]. His6-tagged
ERK was expressed and purified as previously described
[17]. The plasmid for Bad was provided by Dr. Michael
Greenberg (Harvard University). Transient expression of
Bad and caspase 9 (C287A) in HeLa cells was done
using Lipofectamine (Invitrogen).
Immunoblotting
Cells were washed with cold phosphate buffered saline
(PBS, pH 7.2; Invitrogen) and protein lysates were col-
lected with 2× SDS-PAGE sample buffer (4% SDS, 5.7 M
b-mercaptoethanol, 0.2 M Tris pH 6.8, 20% glycerol,
5 mM EDTA) or cold tissue lysis buffer (TLB; 20 mM
Tris-HCl pH 7.4, 137 mM NaCl, 2 mM EDTA, 1% Triton
X-100, 0.1% SDS, 25 mM b-glycerophosphate, 2 mM
sodium pyrophosphate, 10% glycerol, 1 mM sodium
orthovanadate, 1 mM phenylmethylsulfonyl fluoride,
1 mM benzamidine). Lysates collected in TLB were centri-
fuged at 20,000 (× g) to remove insoluble material and
then diluted with an equal volume of 2× SDS-sample buf-
fer. Proteins were separated by SDS-PAGE and analyzed
by immunoblotting using enhanced chemiluminesence
(ECL, GE Healthcare, United Kingdom). The relative pro-
tein levels were determined by densitometry scanning
(Alpha Innotech), keeping the pixel intensity within the
linear range of detection.
Fluorescence Quenching Assay
Fluorescence quenching of 1 μM ERK2 was evaluated by
spectra analysis (SpectraMax5, Molecular Devices) utiliz-
ing an excitation wavelength of 295 nm and the emis-
sion spectra was monitored from 300 to 500 nm in the
presence or absence of 25 μM of the indicated test com-
pound. Relative changes in ERK2 fluorescence intensity
in presence of test compounds were compared to ERK2
fluorescence in the presence of DMSO vehicle only.
Cell proliferation assays
Cell proliferation was evaluated by colony formation or
by water soluble tetrazolium-1 (WST-1) assays. For col-
ony formation, cells (~250 cells/mL) were plated and
allowed to recover for 24 hours before treatment with
test compounds. Cells were grown for 10-14 days and
colonies that formed (approximately 40 cells or more)
were fixed for 10 minutes in 4% paraformaldehyde and
stained with 0.2% crystal violet in 20% methanol for 1-2
minutes. The number of colonies in the treated samples
was expressed as a percentage of the controls, which con-
sisted of 75, 146, or 154 colonies from 3 separate experi-
ments, respectively. WST-1 assay was done according to
manufacturer’s instructions and cleavage of WST-1 to
formazan by cellular mitochondrial dehydrogenases is
used as an indicator of viable cells. Briefly, cells (~250/
mL) were seeded in 96 well plates and allowed to recover
o v e r n i g h tf o l l o w e db yt e s tc o m p o u n dt r e a t m e n tf o r7
days. WST-1 reagent was added and absorbance was read
at 450 nm with background readings taken at 650 nm.
After background subtraction, values were normalized to
the control (DMSO only) cells.
Kinase assays
Active ERK2 (2 ng, New England BioLabs, Ipswich, MA)
was incubated with 0.5 μgH i s 6-tagged caspase 9
(C287A) or p90RSK-1 for 60 minutes at 30°C in 50 mM
Tris-HCl, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT,
0.01% Brij 35 (pH 7.5) containing 20 μMA T Pa n d2
μCi g-
32P-ATP. Reactions were stopped with an equal
volume of 2× SDS-PAGE sample buffer and the proteins
were resolved by SDS-PAGE. The gels were stained with
coomassie blue, dried, and
32P incorporation into sub-
strate was determined by phosphoimager analysis.
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HeLa cells were seeded at equal density and treated with
indicated compound for 5 hours. Cells were harvested
and frozen at -20°C. Fluorometric kits (Calbiochem)
were used according to manufacturer’s instructions to
determine the activity of caspases-8 and 9 in cell lysates.
Briefly, cell pellets were resuspended with 100 μLs a m -
ple buffer and incubated on ice for 10 minutes. Samples
were centrifuged at 10,000 × g for 10 minutes at 4°C;
50 μL of clarified lysate was transferred to a black
walled 96 well plate and 50 μL of assay buffer was
added. Fluorescent caspase substrate was added and a
baseline reading was taken utilizing 400 nm/505 nm
excitation/emission filters. The plates were incubated at
37°C for two hours and read again utilizing the same fil-
ters as baseline. Data shown reflects the mean difference
± SEM of relative fluorescence units (RFU) for three
independent experiments.
Annexin-V/Propidium Iodide Staining
HeLa cells were plated at equal density and treated with
50 μM of indicated test compound. Cells were washed
and stained according to manufacturers protocol
(Calbiochem). Briefly, ~5×10
5 cells were incubated for
15 minutes with AnnexinV-FITC. Cells were centrifuged
at 1,000 × g for 5 minutes and resuspended in 0.5 mL
of cold 1× binding buffer. Propidium Iodide (PI) was
added and samples were immediately analyzed by flow
cytometry (FACScan Analyser; Becton Dickinson, Frank-
lin Lakes, NJ)
Statistical Analysis
Comparisons between control or EGF and treated sam-
ples were performed utilizing an unpaired students
t-test with equal variance using KaleidaGraph software
(Synergy Software, Reading, PA). Comparisons within
treated groups were performed utilizing a one-way ana-
lysis of variance (ANOVA) followed by a Tukey’sp o s t
hoc analysis with an a-value of 0.05. Statistical signifi-
cance was indicated with an asterisk (*) if the p value
was equal to or less than 0.05 or a number sign (#) if
the p value was equal to or less than 0.01.
Results
ERK docking domain inhibitors inhibit cell proliferation
We have previously used computational and cell-based
assays to identify LMW compounds that interact with
ERK2, inhibit phosphorylation of ERK substrates, and
inhibit cell proliferation [17,18,32]. The current studies
used a computational search to identify additional com-
pounds that share chemical features with two previously
identified active compounds, referred to as 17 and 76
[17]. The search was based on the chemical similarity
using the MAC-BITS fingerprints in conjunction with
the Tanimoto Similarity index to search a virtual data-
base of over 1 million commercially available com-
pounds as described [33]. From this computational
search, 5 compounds similar to 17 and 10 compounds
similar to 76 were selected (Figure 1) and tested for
inhibition of cell proliferation. Similar to 76,t e s tc o m -
pounds 76.2, 76.3,a n d76.4 inhibited proliferation of
HeLa cells at 100 μM( F i g u r e2 A )a n do t h e rt r a n s -
formed cell lines from pancreatic, melanoma, colon, and
breast cancer tissue (Table 1). However, compounds
similar to 17 had little effect on cell proliferation and
were not pursued further in the current studies. Each of
the compounds that inhibited cell proliferation showed
interactions with ERK2 (Figure 2B) using fluorescence
quenching assays that we previously described for the
parent compound 76 [17]. Inhibition of HeLa cell prolif-
eration was dose dependent for compounds 76.2, 76.3,
and 76.4 (Table 2). Importantly, non-transformed
epithelial cells that have been immortalized by stable
expression of human telomerase reverse transcriptase
(TERT) were less sensitive to the growth inhibitory
effects of 76.3 or 76.4 (Table 2). TERT cells are useful
cell culture controls for drug discovery as they retain
relatively normal geno- and phenotypes and do not
acquire cancer cell characteristics [34]. However, com-
pounds 76 and 76.2 had similar potencies for inhibiting
HeLa or TERT cell proliferation. Although the common
chemical features of compounds 76.2, 76.3, 76.4 and
the parent compound 76 include a thiazolidinedione
core with an aminoethyl side group (Figure 1), the
effects on cell proliferation suggest that the test com-
pounds may have differences in their mechanisms of
action.
Activation of intrinsic apoptosis by ERK inhibitors
To evaluate whether the changes in proliferation were
linked to an apoptotic response, cells were treated with
test compounds at 50 μM, which resulted in at least
50% inhibition of HeLa cell proliferation (Table 2), and
examined for cleavage of poly-ADP ribose polymerase
(PARP) as a marker of apoptosis. Compounds 76, 76.2,
76.3,a n d76.4 induced PARP cleavage and annexin V/
PI staining after 5 hours exposure (Figure 3A) and this
response could be blocked with a general caspase inhibi-
tor, Z-VAD-FMK (Figure 3B). In contrast, PARP clea-
vage was not observed in TERT cells even after longer
(16 hour) exposures to the test compounds (Figure 3C).
To determine whether the test compounds induced
apoptosis through extrinsic or intrinsic mechanisms,
caspase-8 and 9 activities were examined. Compounds
that induced PARP cleavage also induced caspase-9
activity but had little effect on caspase-8 activity indicat-
i n gt h a tE R K - t a r g e t e dt e s tc o m p o u n d sa c t i v a t ea n
intrinsic apoptosis pathway (Figure 3D).
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p90 Rsk-1 and Bad proteins
ERK proteins provide a survival advantage by directly or
indirectly phosphorylating and inactivating the Bcl-2
family members of pro-apoptotic proteins [3,4]. Bad is a
pro-apoptotic Bcl-2 family member that is inactivated by
phosphorylation at S112 by p90RSK-1 and S136 by Akt
[4,35]. The intrinsic mechanisms of apoptosis induction
by the test compounds were first examined by evaluating
ERK-mediated phosphorylation of p90Rsk-1. Phosphory-
lation of p90Rsk-1 was inhibited by 40, 54, and 67% in
the presence of 50 μM of test compound 76.2, 76.3,a n d
76.4, respectively (Figure 4A). As expected, 76.1,w h i c h
was less effective in inhibiting cell proliferation, did not
inhibit p90Rsk-1 phosphorylation (Figure 4A). It was also
somewhat surprising that 76 did not affect p90Rsk-1
phosphorylation at this dose although 2 fold higher doses
did inhibit p90Rsk-1 phosphorylation by 50% in our pre-
vious studies [17]. None of the compounds caused a sta-
tistically significant inhibition of ERK1/2 activation.
These compounds are predicted to target ERK2 near the
CD domain and may affect ERK activation by upstream
MEK1/2 proteins, which reportedly interact with ERK
through the CD domain [36]. Nonetheless, compounds
76.3,a n d76.4 appeared to show selectivity for inhibiting
ERK-mediated phosphorylation of p90Rsk-1 without
inhibiting ERK activation. Similarly, 76.3 was the most
potent inhibitor of phosphate incorporation into p90Rsk-
1 as measured using in vitro kinase assays and statistically
more potent than the parent compound 76 at 25 μM
(Figure 4B).
We next examined Bad phosphorylation at S112 and
S136 in HeLa cells treated with test compounds. Com-
pounds 76.3 and 76.4 appeared the most potent inhibitors
and reduced EGF-induced S112 phosphorylation by ~75-
80% (Figure 4C). In contrast, S136 phosphorylation in the
presence of these compounds was inhibited by ~40%,
which supports a selective inhibition of the ERK/p90Rsk-1
over Akt signaling. As controls, the MEK1/2 inhibitor,
U0126, inhibited phosphorylation of S112 but not S136,
whereas the PI3K inhibitor, LY294002, inhibited phos-
phorylation of both S112 and S136 (Figure 4C) consistent
with studies suggesting that phosphorylation of S136
induces a conformational change in Bad to promotes
access to kinases that phosphorylate other sites [37].
Test compounds affect the expression of pro- and anti-
apoptotic proteins Bad and Mcl-1
We also examined the test compounds effects on pro-
tein expression of Bad as well as Mcl-1, which is stabi-
lized following ERK phosphorylation [38]. Although a
two-fold increase in total Bad expression was observed
17.1 17.2
17.5
17
17.4
76
76.2
76.1
76.3
76.4
76.5
76.6
76.7
76.9
76.10
76.8
Figure 1 Structure of test compounds used in these studies. The area circled represents the thiazolidinedione core with aminoethyl side
group that is common to compounds showing similar biological activity.
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pounds (Figure 5), these data were not statistically sig-
nificant. Nonetheless, these findings support previous
studies showing increased Bad expression following inhi-
bition of the ERK pathway with the MEK1/2 inhibitor,
PD98059 [39]. However, the test compounds caused a
statistically significant decrease in the expression of the
anti-apoptotic protein Mcl-1 (Figure 5). Thus, these data
indicate that the test compounds may sensitize cells to
undergo apoptosis by increasing the expression of pro-
apoptotic proteins and decreasing the expression of
anti-apoptotic proteins, which are regulated by the ERK
pathway.
Test compounds inhibit caspase-9 phosphorylation
ERK phosphorylation of caspase-9 inhibits caspase-9
proteolytic activity and provides another mechanism by
which activated ERK proteins mediate cell survival [2].
The effects of test compounds on ERK-mediated phos-
phorylation of caspase-9 on T125 were examined by
immunoblotting lysates from cells where the ERK path-
way was stimulated with EGF. Apoptosis-inducing test
compounds 76, 76.2, 76.3, and 76.4, inhibited caspase-9
phosphorylation by 50-60% in treated cells (Figure 6A).
Next, active ERK2 was incubated with caspase-9 protein
in the absence or presence of test compounds and phos-
phorylation was examined using in vitro kinase assays.
Figure 6B shows that compounds 76, 76.2, 76.3,a n d
76.4 inhibited ERK-mediated phosphorylation of cas-
pase-9 in a dose dependent manner. While 76.3
appeared to be the more potent inhibitor of caspase-9
phosphorylation, there was no statistical difference
between compounds at any of the doses.
Discussion
The goal of these studies was to characterize a class of
novel ERK inhibitor compounds being developed in our
laboratory that inhibit cell proliferation. Our findings
demonstrate the induction of an apoptotic response by
structurally-related compounds that inhibit ERK regula-
tion of pro-apoptotic proteins. Aberrant activation of
ERK signaling has been well-documented and provides a
survival advantage in a number of cancers by inactivating
pro-apoptotic proteins [40]. Thus, selective inhibition of
#
#
# #
A.
B.
Figure 2 Effects of ERK targeted docking domain inhibitors on
cell proliferation. (A) HeLa cells were seeded at 250 cells/mL in
the presence or absence of 100 uM of the indicated test
compound. After 10-14 days, cell colonies were fixed with
formaldehyde and stained with crystal violet. Colonies were
counted and normalized to the controls for each experiment. Data
represent mean ± SD from 3 experiments. # indicates statistical
significance compared to untreated controls p ≤ 0.01. C, Control.
(B) Fluorescence quenching of ERK2 in the presence of test
compounds. Data show the mean ± SD for percent fluorescence
quenching as compared to ERK2 fluorescence in the presence of
vehicle (DMSO) from 3 independent experiments.
Table 1 Effects of ERK targeted docking domain
inhibitors on proliferation of cancer cell lines
Compound HeLa SUM159 HCT-116 SKMEL-28 Panc-1
76 ++ ++ ND ++ ++
76.1 -+ + - - N D
76.2 ++ ++ ++ ++ ND
76.3 ++ ++ ++ ++ ND
76.4 ++ ++ ++ + -
76.5 -- - - N D
76.6 -- - - N D
76.7 -- - - N D
76.8 -- - - N D
76.9 + - ++ + ND
76.10 -- - - N D
17 +N D N D - N D
17.1 -- - - N D
17.2 ++ + + + + N D
17.3 -- - - N D
17.4 -- - - N D
17.5 -- - - N D
Transformed cell lines from cervical (HeLa), breast (SUM159), colon (HCT-116),
skin (SKMEL-28), or pancreatic (Panc-1) tissue were treated for 7 days with 100
μM of the indicated test compound. The proliferation in treated cells is shown
relative to control (DMSO only) following analysis using the colony formation
assay. (-) ≤ 25%, (+) 25-75%, and (++) ≥75% inhibition; ND, No data.
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sensitize cancer cells to chemotherapeutic agents. One
important feature of the active test compounds is that
some appear to be more selective for decreasing cell pro-
liferation and inducing apoptosis in transformed cells as
compared to non-transformed cells (Table 2 and
Figure 3). This finding is in agreement with our previous
studies indicating that the test compounds did not affect
the life span or cause general toxicity in a C. elegans
whole organism model [32]. Interestingly, we also have
Table 2 Effects of ERK targeted docking domain inhibitors on cell proliferation
76 76.2 76.3 76.4
HeLa TERT HeLa TERT HeLa TERT HeLa TERT
25 μM 20.1 ± 5.2
# 21.7 ± 3.6
# 73.7 ± 12.6 81.0 ± 8.1 58.2 ± 7.4
# 112.9 ± 19.1 53.7 ± 6.0
# 120.0 ± 26.5
50 μM 20.4 ± 4.1
# 23.5 ± 12.0* 31.2 ± 12.9
# 16.2 ± 4.0
# 40.1 ± 8.0
# 127.8 ± 12.8 36.3 ± 7.4
# 48.1 ± 11.7
#
100 μM 20.5 ± 5.9
# 29.3 ± 12.1* 17.3 ± 7.1
# 19.9 ± 12.5
# 17.1 ± 6.1
# 53.6 ± 6.8
# 21.0 ± 6.3
# 45.4 ± 12.6
#
HeLa or non-transformed retinal pigment epithelial cells that stably express human telomerase reverse transcriptase (TERT) were seeded at 250 cells/mL and then
treated for 7 days with 25-100 uM of the indicated test compound. The proliferation in treated cells is shown as a percentage of control cells (DMSO only set at
100%) following analysis using the WST-1 assay. Data represent mean ± SEM from 3 experiments. * and # indicates statistical significance compared to untreated
controls, p ≤ 0.05 and p ≤ 0.01, respectively.
C.
C 
76.4
76.3
76.2
76.1 
76 
E 
A.
C 
76.10
76.9
76.8
76.7
76.6
76.5
76.4
76.3
76.2
76.1 
76 
D.
*
*
*
*
Cleaved Parp
α-tubulin
B.
  -     +      -      +      -      +      -      + ZVAD-FMK
76 76.2 76.3 76.4
* #
#
Figure 3 Test compounds induce the intrinsic apoptosis pathway.H e L a( A) or TERT (C) cells were treated in the absence or presence of
test compounds (50 uM) for 5 hours (HeLa) or 16 hours (TERT). Cell lysates were immunoblotted for total and cleaved PARP (arrowhead). Graph
on the right shows densitometry quantification of cleaved PARP to a-tubulin ratios and annexinV/PI staining relative control. PARP data
represents the mean ± SEM from four independent experiments; annexinV/PI data are representative of two independent experiments. (B) HeLa
cells were treated with 50 uM of the indicated compound for 5 hours and assayed for cleaved PARP in the presence and absence of the general
caspase inhibitor ZVAD-FMK. (D) HeLa cells were treated in the absence or presence of 50 uM of the indicated compound for 5 hours and
assayed for caspase 8 or 9 activity. Data represent the mean ± SEM from 3 independent experiments. * and # indicates statistical significance
compared to untreated controls, p ≤ 0.05 and p ≤ 0.01, respectively. C, Control; E, Etoposide.
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Figure 4 Test compounds inhibit ERK-mediated phosphorylation of p90Rsk-1 and Bad.( A) HeLa cells were pre-treated for one hour in the
presence or absence of 50 uM of the indicated test compounds and then stimulated with EGF (25 ng/ml) for 10 minutes. Immunoblots of
phosphorylated p90Rsk-1 (pRsk), total Rsk (Rsk), phosphorylated ERK1/2 (ppERK), and total ERK2 (ERK2). a-tubulin was used as a loading control.
Graph shows densitometry quantification of pRsk-1 to total Rsk or ppERK2 to ERK2 ratios. Data represents the mean ± SEM from three
independent experiments. (B) In vitro kinase assays examining
32P incorporation into p90Rsk-1 following incubation with active ERK2 and g-
32P-
ATP for 60 min. in the absence or presence of 1-25 μM of test compounds. Relative phosphate incorporation was quantified by phosphoimager
analysis. (C) HeLa cells were serum starved overnight and pre-treated for 1 hr with 50 uM indicated test compounds, 10 mM U0126 (U), or 25
mM LY294002 (L) prior to stimulation with or without EGF (25 ng/ml). Immunoblot analysis of Bad phosphorylated on Ser112 (pS112) or Ser136
(pS136) and total Bad. a-tubulin was used as a loading control. Data represents the mean ± SEM from three independent experiments. * and #
indicates statistical significance compared to EGF-only treatment (A and C) or untreated controls (B), p ≤ 0.05 and p ≤ 0.01, respectively. C,
untreated control; (-) EGF treated control.
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Page 8 of 12not observed overt toxicity when treating mice harboring
B-cell lymphomas with compound 76 [41]. Coinciden-
tally, these in vivo studies also demonstrated that B-cell
lymphoma tumor burden was significantly reduced by
76. However, we predict that the significance of the ERK-
targeted inhibitors in reducing tumor burden will best be
realized using potentially more potent compounds, such
as 76.3, in combination with other chemotherapeutic
agents.
Our data support a mechanism by which the ERK-tar-
geted compounds prevent inactivation of caspase-9 and
p90Rsk-1 phosphorylation of Bad (Figures 4 and 6).
Both caspase-9 and p90Rsk-1 contain D-domains that
are thought to form contacts with the CD domain of
ERK proteins [1,24]; the region predicted to be targeted
by the test compounds. Structural studies underway are
determining the site of interactions between the com-
pounds and ERK proteins to better understand the
mechanisms of inhibition and identify chemical features
that can be modified to improve inhibitor binding and
efficacy. A region analogous to the CD domain of ERK
can be found on other MAP kinases family members
including p38 and JNK [29,42]. The subtle differences
between these regions are determinants of substrate
selectivity between the MAP kinases. In addition, differ-
ences in the residues associated with the D-domains of
MAP kinase interacting proteins can confer selectivity.
For example, the differences in D-domains on MAP
kinase kinase (MKK) proteins appear to be important
for determining what MAP kinase the MKK isoform
will target [43].
The p90Rsk-1 protein is a major regulator of ERK-
mediated cell survival [5] and, like Bad, other p90Rsk-1
substrates may be affected by the test compounds.
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Figure 5 Test compounds affect the expression of the pro- and
anti-apoptotic proteins, Bad and Mcl-1, respectively. Total Bad
and Mcl-1 immunoblots from lysates collected from HeLa cells
treated for 16 hour with 50 μM of indicated test compounds (top
panel) and fold expression quantified by densitometry (bottom
panel). a-tubulin was used as a loading control. Data represent the
mean ± SEM of three independent experiments. # indicates
statistical significance compared to untreated controls, p ≤ 0.01. C,
Control.
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Figure 6 Test compounds inhibit ERK-mediated
phosphorylation of caspase-9 in cells and in in vitro kinase
assays.( A) HeLa cells transfected with caspase-9 (C287A) were pre-
treated for 1 hour with 50 uM of indicated test compound,
stimulated with EGF (25 ng/ml), and immunoblotted for
phosphorylated caspase-9 (pT125) or total caspase-9. Graph shows
the mean ± SEM for relative phosphorylation as determined by
densitometry scanning from 3 independent experiments. (B) In vitro
kinase assays examining
32P incorporation into caspase-9 following
incubation with active ERK2 and g-
32P-ATP for 60 min. in the
absence or presence of 1-25 μM of the indicated test compound.
Relative phosphate incorporation was quantified by phosphoimager
analysis. Data show the mean ± SEM of three independent
experiments. * and # indicates statistical significance compared to
EGF-only treatment (A) or untreated controls (B), p ≤ 0.05 and p ≤
0.01, respectively. C, untreated control; (-), EGF treated control; U,
U0126.
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Page 9 of 12For example, inhibition of p90Rsk-1 could also restore
activity of the death associated protein kinase (DAPK),
which is a pro-apoptotic tumor suppressor protein that
is phosphorylated and inactivated by p90Rsk-1 [44].
Moreover, it is recognized that other survival proteins
may be affected by the test compounds and involved in
mediating the apoptotic response observed. While some
inhibition of PI3K/Akt signaling may have occurred
with the test compounds (data not shown), these effects
were not to the extent of inhibition of Akt substrates
with the PI3K inhibitor, LY294002. In addition, the acti-
vation of other growth related proteins like ERK5 and
EGF receptor (data not shown) were not affected, which
further supports the mechanism of apoptosis induction
by the test compounds involves inhibition of ERK1/2
signaling.
Another objective of this study was to determine
whether improvements in potency and selectivity of the
parent compound (76) could be achieved by examining
structurally similar compounds. Cell based and in vitro
kinase assays in figures 4 and 6 suggest that compound
76.3 has higher potency than 76. Thus, these studies
have identified a class of structurally similar compounds
that have similar biological effects and chemical features
that can be modified to improve potency. Studies are
now aimed at performing a more detailed structure
activity relationship to identify the mode of the com-
pound’s interaction with ERK, improve potency, and
determine whether other substrate proteins are affected.
The present results also indicate the potential utility of
using LMW compounds that inhibit protein-protein
interactions in a therapeutic setting. While it has tradi-
tionally been assumed that small compounds would not
be effective inhibitors of protein-protein interactions
[45,46], recent studies involving the transcription factor
BCL6 indicate that protein-protein interactions can be
targeted in vivo with LMW compounds [47]. The effi-
cacy of the present compounds as inhibitors of ERK-
substrate interactions and their activity in a xenograft
mouse model [41] further indicate that protein-protein
interactions are valid therapeutic targets of LMW
compounds.
The specific targeting of the ERK1/2 pathway to treat
cancer has been best studied using MEK1/2 inhibitors
(reviewed in [48]). Although a number of preclinical stu-
dies showed very good efficacy of MEK inhibitors for
reducing cancer cell proliferation and inducing apopto-
sis, patient responses in clinical trials have been minimal
with these compounds as single agents. Thus, MEK
inhibitors in combination with other chemotherapeutic
drugs will likely be more effective. A potential problem
with targeting MEK for cancer therapy is the develop-
ment of drug resistance, possibly through compensatory
mechanisms involving elevated expression and activity
of MEK/ERK proteins [49]. Thus, the approach to com-
pletely inhibit MEK/ERK signaling may be counterpro-
ductive in the long term. In contrast, the use of
compounds that selectively inhibit ERK functions
involved in cell survival may have the potential to sensi-
tize cancer cells to other chemotherapeutic agents with-
out inducing the compensatory pathways that lead to
acquired drug resistance.
Conclusion
We have identified a class of LMW compounds that are
selective for ERK docking domains involved in regulating
interactions with substrates that promote cell prolifera-
tion and survival. These new compounds inhibit trans-
formed cell proliferation and induce apoptosis, in part, by
inhibiting substrate phosphorylation events that regulate
pro- and anti-apoptotic proteins. Future optimization of
the chemical features of the new lead compounds may
provide more potent and selective molecules that can
improve the efficacy of existing chemotherapeutic agents
by disabling some of ERK1/2 protein functions.
Acknowledgements
The authors would like to thank Dr. Michael Greenberg (Harvard University)
for kindly providing the Bad plasmid. The project was supported by
R01CA120215 (SB and PS) from the National Cancer Institute. The content is
solely the responsibility of the authors and does not necessarily represent
the official views of the National Cancer Institute or the National Institutes of
Health.
Author details
1Department of Pharmaceutical Sciences, School of Pharmacy, University of
Maryland 20 N. Pine St. Baltimore, MD 21201 USA.
2Department of
Otorhinolaryngology, School of Medicine, University of Maryland 16 S. Eutaw
St. Baltimore, MD 21201 USA.
Authors’ contributions
SB participated in study design, performed the experiments and statistical
analysis as well as writing the manuscript. RD performed the colony
formation assays. UP and AM designed the ERK targeted docking domain
inhibitors. SS provided valuable insight and critically reviewed the
manuscript. AM and PS participated in the conception and study design. PS
coordinated the study and the writing of the manuscript. All authors
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 24 August 2010 Accepted: 10 January 2011
Published: 10 January 2011
References
1. Martin MC, Allan LA, Mancini EJ, Clarke PR: The docking interaction of
caspase-9 with ERK2 provides a mechanism for the selective inhibitory
phosphorylation of caspase-9 at threonine 125. J Biol Chem 2008,
283:3854-3865.
2. Allan LA, Morrice N, Brady S, Magee G, Pathak S, Clarke PR: Inhibition of
caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell
Biol 2003, 5:647-654.
3. Harada H, Quearry B, Ruiz-Vela A, Korsmeyer SJ: Survival factor-induced
extracellular signal-regulated kinase phosphorylates BIM, inhibiting its
association with BAX and proapoptotic activity. Proc Natl Acad Sci USA
2004, 101:15313-15317.
Boston et al. BMC Cancer 2011, 11:7
http://www.biomedcentral.com/1471-2407/11/7
Page 10 of 124. Fang X, Yu S, Eder A, Mao M, Bast RC Jr, Boyd D, Mills GB: Regulation of
BAD phosphorylation at serine 112 by the Ras-mitogen-activated
protein kinase pathway. Oncogene 1999, 18:6635-6640.
5. Shimamura A, Ballif BA, Richards SA, Blenis J: Rsk1 mediates a MEK-MAP
kinase cell survival signal. Curr Biol 2000, 10:127-135.
6. Shapiro P: Ras-MAP kinase signaling pathways and control of cell
proliferation: relevance to cancer therapy. Crit Rev Clin Lab Sci 2002,
39:285-330.
7. Burkhard K, Smith S, Deshmukh R, MacKerell AD Jr, Shapiro P:
Development of extracellular signal-regulated kinase inhibitors. Curr Top
Med Chem 2009, 9:678-689.
8. Sheridan C, Brumatti G, Martin SJ: Oncogenic B-RafV600E inhibits
apoptosis and promotes ERK-dependent inactivation of Bad and Bim. J
Biol Chem 2008, 283:22128-22135.
9. McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A,
Cervello M, Lee JT, Steelman LS: Targeting the Raf/MEK/ERK pathway with
small-molecule inhibitors. Curr Opin Investig Drugs 2008, 9:614-630.
10. Kohno M, Pouyssegur J: Targeting the ERK signaling pathway in cancer
therapy. Ann Med 2006, 38:200-211.
11. Harandi A, Zaidi AS, Stocker AM, Laber DA: Clinical Efficacy and Toxicity of
Anti-EGFR Therapy in Common Cancers. J Oncol 2009, 2009:567486.
12. Grant SK: Therapeutic protein kinase inhibitors. Cell Mol Life Sci 2009,
66:1163-1177.
13. Wallace EM, Lyssikatos JP, Yeh T, Winkler JD, Koch K: Progress towards
therapeutic small molecule MEK inhibitors for use in cancer therapy.
Curr Top Med Chem 2005, 5:215-229.
14. de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M: Cardiac toxicity with
anti-HER-2 therapies: what have we learned so far? Target Oncol 2009,
4:77-88.
15. Al-Dasooqi N, Gibson R, Bowen J, Keefe D: HER2 targeted therapies for
cancer and the gastrointestinal tract. Curr Drug Targets 2009, 10:537-542.
16. Lewis TS, Shapiro PS, Ahn NG: Signal tranduction through MAP Kinase
Cascades. Advances in Cancer Research 1998, 74:49-139.
17. Hancock CN, Macias A, Lee EK, Yu SY, Mackerell AD Jr, Shapiro P:
Identification of novel extracellular signal-regulated kinase docking
domain inhibitors. J Med Chem 2005, 48:4586-4595.
18. Chen F, Hancock CN, Macias AT, Joh J, Still K, Zhong S, MacKerell AD Jr,
Shapiro P: Characterization of ATP-independent ERK inhibitors identified
through in silico analysis of the active ERK2 structure. Bioorg Med Chem
Lett 2006, 16:6281-6287.
19. Sheridan DL, Kong Y, Parker SA, Dalby KN, Turk BE: Substrate
Discrimination among Mitogen-activated Protein Kinases through
Distinct Docking Sequence Motifs. J Biol Chem 2008, 283:19511-19520.
20. Jacobs D, Glossip D, Xing H, Muslin AJ, Kornfeld K: Multiple docking sites
on substrate proteins form a modular system that mediates recognition
by ERK MAP kinase. Genes Dev 1999, 13:163-175.
21. Fantz DA, Jacobs D, Glossip D, Kornfeld K: Docking sites on substrate
proteins direct extracellular signal-regulated kinase to phosphorylate
specific residues. J Biol Chem 2001, 276:27256-27265.
22. Yang SH, Whitmarsh AJ, Davis RJ, Sharrocks AD: Differential targeting of
MAP kinases to the ETS-domain transcription factor Elk-1. Embo J 1998,
17:1740-1749.
23. Sharrocks AD, Yang SH, Galanis A: Docking domains and substrate-
specificity determination for MAP kinases. Trends Biochem Sci 2000,
25:448-453.
24. Dimitri CA, Dowdle W, MacKeigan JP, Blenis J, Murphy LO: Spatially
separate docking sites on ERK2 regulate distinct signaling events in
vivo. Curr Biol 2005, 15:1319-1324.
25. Tanoue T, Adachi M, Moriguchi T, Nishida E: A conserved docking motif in
MAP kinases common to substrates, activators and regulators. Nat Cell
Biol 2000, 2:110-116.
26. Yang SH, Galanis A, Sharrocks AD: Targeting of p38 mitogen-activated
protein kinases to MEF2 transcription factors. Mol Cell Biol 1999,
19:4028-4038.
27. Lee T, Hoofnagle AN, Kabuyama Y, Stroud J, Min X, Goldsmith EJ, Chen L,
Resing KA, Ahn NG: Docking motif interactions in MAP kinases revealed
by hydrogen exchange mass spectrometry. Mol Cell 2004, 14:43-55.
28. Zhou T, Sun L, Humphreys J, Goldsmith EJ: Docking interactions induce
exposure of activation loop in the MAP kinase ERK2. Structure 2006,
14:1011-1019.
29. Tanoue T, Maeda R, Adachi M, Nishida E: Identification of a docking
groove on ERK and p38 MAP kinases that regulates the specificity of
docking interactions. Embo J 2001, 20:466-479.
30. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM,
Alnemri ES, Salvesen GS, Reed JC: IAPs block apoptotic events induced by
caspase-8 and cytochrome c by direct inhibition of distinct caspases.
Embo J 1998, 17:2215-2223.
31. Fisher TL, Blenis J: Evidence for two catalytically active kinase domains in
pp90rsk. Mol Cell Biol 1996, 16:1212-1219.
32. Chen F, Mackerell AD Jr, Luo Y, Shapiro P: Using Caenorhabditis elegans
as a model organism for evaluating extracellular signal-regulated kinase
docking domain inhibitors. J Cell Commun Signal 2008, 2:81-92.
33. Macias AT, Mia MY, Xia G, Hayashi J, MacKerell AD: Lead validation and
SAR development via chemical similarity searching; application to
compounds targeting the pY+3 site of the SH2 domain of p56lck.
J Chem Inf Model 2005, 45:1759-1766.
34. Lee KM, Choi KH, Ouellette MM: Use of exogenous hTERT to immortalize
primary human cells. Cytotechnology 2004, 45:33-38.
35. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt
phosphorylation of BAD couples survival signals to the cell-intrinsic
death machinery. Cell 1997, 91:231-241.
36. Robinson FL, Whitehurst AW, Raman M, Cobb MH: Identification of novel
point mutations in ERK2 that selectively disrupt binding to MEK1. J Biol
Chem 2002, 277:14844-14852.
37. Datta SR, Katsov A, Hu L, Petros A, Fesik SW, Yaffe MB, Greenberg ME: 14-3-
3 proteins and survival kinases cooperate to inactivate BAD by BH3
domain phosphorylation. Mol Cell 2000, 6:41-51.
38. Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW: MCL1 is
phosphorylated in the PEST region and stabilized upon ERK activation in
viable cells, and at additional sites with cytotoxic okadaic acid or taxol.
Oncogene 2004, 23:5301-5315.
39. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N: MEK/ERK
signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1
and promotes survival of human pancreatic cancer cells. J Cell Biochem
2000, 79:355-369.
40. Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL,
Franklin R, McCubrey JA: Regulation of cell cycle progression and
apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol 2003,
22:469-480.
41. Dai B, Zhao XF, Hagner P, Shapiro P, Mazan-Mamczarz K, Zhao S,
Natkunam Y, Gartenhaus RB: Extracellular signal-regulated kinase
positively regulates the oncogenic activity of MCT-1 in diffuse large B-
cell lymphoma. Cancer Res 2009, 69:7835-7843.
42. Heo YS, Kim SK, Seo CI, Kim YK, Sung BJ, Lee HS, Lee JI, Park SY, Kim JH,
Hwang KY, et al: Structural basis for the selective inhibition of JNK1
by the scaffolding protein JIP1 and SP600125. Embo J 2004,
23:2185-2195.
43. Bardwell AJ, Frankson E, Bardwell L: Selectivity of docking sites in MAPK
kinases. J Biol Chem 2009, 284:13165-13173.
44. Anjum R, Roux PP, Ballif BA, Gygi SP, Blenis J: The tumor suppressor DAP
kinase is a target of RSK-mediated survival signaling. Curr Biol 2005,
15:1762-1767.
45. Juliano RL, Astriab-Fisher A, Falke D: Macromolecular therapeutics:
emerging strategies for drug discovery in the postgenome era. Mol
Interv 2001, 1:40-53.
46. Kuntz ID: Structure-based strategies for drug design and discovery.
Science 1992, 257:1078-1082.
47. Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M,
Bunting KL, Polo JM, Fares C, Arrowsmith CH, et al: A small-molecule
inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 2010,
17:400-411.
48. Friday BB, Adjei AA: Advances in targeting the Ras/Raf/MEK/Erk mitogen-
activated protein kinase cascade with MEK inhibitors for cancer therapy.
Clin Cancer Res 2008, 14:342-346.
Boston et al. BMC Cancer 2011, 11:7
http://www.biomedcentral.com/1471-2407/11/7
Page 11 of 1249. Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM:
Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors
correlates with up-regulation of the MEK/extracellular signal-regulated
kinase pathway in hepatocellular carcinoma cells. J Pharmacol Exp Ther
2009, 329:1063-1070.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/11/7/prepub
doi:10.1186/1471-2407-11-7
Cite this article as: Boston et al.: Characterization of ERK Docking
Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and
Caspase-9. BMC Cancer 2011 11:7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Boston et al. BMC Cancer 2011, 11:7
http://www.biomedcentral.com/1471-2407/11/7
Page 12 of 12